KLF14/miR-1283/TFAP2C axis inhibits HER2-positive breast cancer progression via declining tumor cell proliferation

Xue-Zhong Chen1, Wen-Xing He1, Rong-Guang Luo1

  • 1Department of Nuclear Medicine/Radiology, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Molecular Carcinogenesis
|February 8, 2023
PubMed

Insights

MicroRNA-1283 (miR-1283) acts as a tumor suppressor in HER2-positive breast cancer by inhibiting proliferation and promoting apoptosis. The KLF14/miR-1283/TFAP2C pathway suppresses tumor growth, offering new therapeutic insights.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNA-1283 (miR-1283) is a known tumor suppressor, but its role in HER2-positive (HER2+) breast cancer, especially concerning cell proliferation, remains unclear.
  • HER2+ breast cancer is characterized by uncontrolled cell proliferation, a key driver of tumor progression.

Purpose of the Study:

  • To investigate the function of miR-1283 in HER2+ breast cancer proliferation and apoptosis.
  • To elucidate the molecular mechanisms underlying miR-1283's role, including its targets and regulatory factors.

Main Methods:

  • Screening of microRNAs from HER2+ breast cancer datasets (GSE131599).
  • Overexpression of miR-1283 in HER2+ breast cancer cell lines (SKBR3, BT-474) and functional assays (proliferation, apoptosis).
  • Xenograft mouse models to assess tumor growth inhibition. Target prediction and validation (TFAP2C, KLF14).

Main Results:

  • miR-1283 expression was significantly decreased in HER2+ breast cancer tissues and cell lines.
  • Overexpression of miR-1283 suppressed cell proliferation, induced apoptosis, and inhibited tumor growth in vivo.
  • miR-1283 directly targets TFAP2C mRNA, and KLF14 enhances miR-1283 expression by binding to its promoter.

Conclusions:

  • The KLF14/miR-1283/TFAP2C signaling axis plays a crucial role in suppressing cell proliferation in HER2+ breast cancer.
  • This pathway represents a potential therapeutic target for inhibiting HER2+ breast cancer progression.